Microscopic Colitis: Clinical and Pathologic Perspectives

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 2, 2015, Pages 228-236

  Münch, Andreas ^a   Langner, Cord ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Colon; EMCG; Immune response; Therapy

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; AZATHIOPRINE; BISMUTH SALICYLATE; BUDESONIDE; LANSOPRAZOLE; LOPERAMIDE; MERCAPTOPURINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RANITIDINE; RUSCUS ACULEATUS EXTRACT; SERTRALINE; TICLOPIDINE; ANTIINFLAMMATORY AGENT;

ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; COLLAGENOUS COLITIS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; FAMILIAL DISEASE; GENETICS; HEREDITY; HISTOPATHOLOGY; HUMAN; IMMUNOLOGY; LYMPHOCYTIC COLITIS; MAINTENANCE THERAPY; MICROSCOPIC COLITIS; PATHOGENESIS; PATHOPHYSIOLOGY; QUALITY OF LIFE; RISK FACTOR; SMOKING; COLITIS, MICROSCOPIC; PATHOLOGY; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; BUDESONIDE; COLITIS, MICROSCOPIC; HUMANS; TREATMENT OUTCOME;

EID: 84927690479     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.12.026     Document Type: Review

References (66)

1. Munch A., Aust D., Bohr J., et al. Microscopic colitis: current status, present and future challenges: statements of the European Microscopic Colitis Group. JCrohns Colitis 2012, 6:932-945.
2. Olesen M., Eriksson S., Bohr J., et al. Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998. Gut 2004, 53:346-350.
3. Hjortswang H., Tysk C., Bohr J., et al. Health-related quality of life is impaired in active collagenous colitis. Dig Liver Dis 2011, 43:102-109.
4. Chande N., MacDonald J.K., McDonald J.W. Interventions for treating microscopic colitis: a Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Review Group systematic review of randomized trials. Am J Gastroenterol 2009, 104:235-241. quiz 234, 242.
5. Miehlke S., Madisch A., Voss C., et al. Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide. Aliment Pharmacol Ther 2005, 22:1115-1119.
6. Gentile NM, Khanna S, Loftus EV, et al. The epidemiology of microscopic colitis in Olmsted County from 2002 to 2010: a population-based study. Clin Gastroenterol Hepatol 2013 Oct 9. Epub ahead of print.
7. Wickbom A., Bohr J., Eriksson S., et al. Stable incidence of collagenous colitis and lymphocytic colitis in Orebro, Sweden, 1999-2008: a continuous epidemiologic study. Inflamm Bowel Dis 2013, 19:2387-2393.
8. Bohr J., Tysk C., Eriksson S., et al. Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. Gut 1996, 39:846-851.
9. El-Matary W., Girgis S., Huynh H., et al. Microscopic colitis in children. Dig Dis Sci 2010, 55:1996-2001.
10. Bjornbak C., Engel P.J., Nielsen P.L., et al. Microscopic colitis: clinical findings, topography and persistence of histopathological subgroups. Aliment Pharmacol Ther 2011, 34:1225-1234.
11. Bonderup O.K., Hansen J.B., Teglbjaerg P.S., et al. Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial. Gut 2009, 58:68-72.
12. Münch A., Benoni C., Olesen M., et al. Budesonide induces clinical remission and improves quality of life in active collagenous colitis: results from the open-label induction phase of BUC-63/COC (abstr). JCrohns Colitis 2013, 7(Suppl I). S238(P567).
13. Hjortswang H., Tysk C., Bohr J., et al. Defining clinical criteria for clinical remission and disease activity in collagenous colitis. Inflamm Bowel Dis 2009, 15:1875-1881.
14. Abboud R., Pardi D.S., Tremaine W.J., et al. Symptomatic overlap between microscopic colitis and irritable bowel syndrome: a prospective study. Inflamm Bowel Dis 2013, 19:550-553.
15. Vigren L., Tysk C., Strom M., et al. Celiac disease and other autoimmune diseases in patients with collagenous colitis. Scand J Gastroenterol 2013, 48:944-950.
16. Chan J.L., Tersmette A.C., Offerhaus G.J., et al. Cancer risk in collagenous colitis. Inflamm Bowel Dis 1999, 5:40-43.
17. O'Mahony O.H., Burgoyne M., Going J.J. Specific histological abnormalities are more likely in biopsies of endoscopically normal large bowel after the age of 60 years. Histopathology 2012, 61:1209-1213.
18. Koulaouzidis A., Saeed A.A. Distinct colonoscopy findings of microscopic colitis: not so microscopic after all?. World J Gastroenterol 2011, 17:4157-4165.
19. Aust D., Münch A., Olesen M., et al. Topographical distribution of collagenous colitis-a pooled histological analysis of 2 European prospective multicenter trials (abstr). Gastroenterology 2013, 144. S-421(Su1183).
20. Magro F., Langner C., Driessen A., et al. European consensus on the histopathology of inflammatory bowel disease. JCrohns Colitis 2013, 7:827-851.
21. Chetty R., Govender D. Lymphocytic and collagenous colitis: an overview of so-called microscopic colitis. Nat Rev Gastroenterol Hepatol 2012, 9:209-218.
22. Yen E.F., Pardi D.S. Review article: microscopic colitis-lymphocytic, collagenous and 'mast cell' colitis. Aliment Pharmacol Ther 2011, 34:21-32.
23. Brown W.R., Tayal S. Microscopic colitis. A review. JDig Dis 2013, 14:277-281.
24. Geboes K. Lymphocytic, collagenous and other microscopic colitides: pathology and the relationship with idiopathic inflammatory bowel diseases. Gastroenterol Clin Biol 2008, 32:689-694.
25. Sapp H., Ithamukkala S., Brien T.P., et al. The terminal ileum is affected in patients with lymphocytic or collagenous colitis. Am J Surg Pathol 2002, 26:1484-1492.
26. Mahajan D., Goldblum J.R., Xiao S.Y., et al. Lymphocytic colitis and collagenous colitis: a review of clinicopathologic features and immunologic abnormalities. Adv Anat Pathol 2012, 19:28-38.
27. Ayata G., Ithamukkala S., Sapp H., et al. Prevalence and significance of inflammatory bowel disease-like morphologic features in collagenous and lymphocytic colitis. Am J Surg Pathol 2002, 26:1414-1423.
28. Muller S., Neureiter D., Stolte M., et al. Tenascin: a sensitive and specific diagnostic marker of minimal collagenous colitis. Virchows Arch 2001, 438:435-441.
29. Lazenby A.J., Yardley J.H., Giardiello F.M., et al. Pitfalls in the diagnosis of collagenous colitis: experience with 75 cases from a registry of collagenous colitis at the Johns Hopkins Hospital. Hum Pathol 1990, 21:905-910.
30. Fraser A.G., Warren B.F., Chandrapala R., et al. Microscopic colitis: a clinical and pathological review. Scand J Gastroenterol 2002, 37:1241-1245.
31. Goldstein N.S., Bhanot P. Paucicellular and asymptomatic lymphocytic colitis: expanding the clinicopathologic spectrum of lymphocytic colitis. Am J Clin Pathol 2004, 122:405-411.
32. Chang F., Deere H., Vu C. Atypical forms of microscopic colitis: morphological features and review of the literature. Adv Anat Pathol 2005, 12:203-211.
33. Jarnerot G., Tysk C., Bohr J., et al. Collagenous colitis and fecal stream diversion. Gastroenterology 1995, 109:449-455.
34. Munch A., Soderholm J.D., Wallon C., et al. Dynamics of mucosal permeability and inflammation in collagenous colitis before, during, and after loop ileostomy. Gut 2005, 54:1126-1128.
35. Abdo A.A., Zetler P.J., Halparin L.S. Familial microscopic colitis. Can J Gastroenterol 2001, 15:341-343.
36. Jarnerot G., Hertervig E., Granno C., et al. Familial occurrence of microscopic colitis: a report on five families. Scand J Gastroenterol 2001, 36:959-962.
37. Fine K.D., Do K., Schulte K., et al. High prevalence of celiac sprue-like HLA-DQ genes and enteropathy in patients with the microscopic colitis syndrome. Am J Gastroenterol 2000, 95:1974-1982.
38. Madisch A., Hellmig S., Schreiber S., et al. Allelic variation of the matrix metalloproteinase-9 gene is associated with collagenous colitis. Inflamm Bowel Dis 2011, 17:2295-2298.
39. Madisch A., Hellmig S., Schreiber S., et al. NOD2/CARD15 gene polymorphisms are not associated with collagenous colitis. Int J Colorectal Dis 2007, 22:425-428.
40. Munch A., Soderholm J.D., Ost A., et al. Increased transmucosal uptake of E. coli K12 in collagenous colitis persists after budesonide treatment. Am J Gastroenterol 2009, 104:679-685.
41. Tagkalidis P.P., Gibson P.R., Bhathal P.S. Microscopic colitis demonstrates a T helper cell type 1 mucosal cytokine profile. JClin Pathol 2007, 60:382-387.
42. Burgel N., Bojarski C., Mankertz J., et al. Mechanisms of diarrhea in collagenous colitis. Gastroenterology 2002, 123:433-443.
43. Bohr J., Jarnerot G., Tysk C., et al. Effect of fasting on diarrhoea in collagenous colitis. Digestion 2002, 65:30-34.
44. Walter S.A., Munch A., Ost A., et al. Anorectal function in patients with collagenous colitis in active and clinically quiescent phase, in comparison with healthy controls. Neurogastroenterol Motil 2010, 22:534-538. e118.
45. Kumawat A.K., Strid H., Elgbratt K., et al. Microscopic colitis patients have increased proportions of Ki67(+) proliferating and CD45RO(+) active/memory CD8(+) and CD4(+)8(+) mucosal T cells. JCrohns Colitis 2013, 7:694-705.
46. Dey I., Beck P.L., Chadee K. Lymphocytic colitis is associated with increased pro-inflammatory cytokine profile and up regulation of prostaglandin receptor EP4. PLoS One 2013, 8:e61891.
47. Kumawat A.K., Strid H., Tysk C., et al. Microscopic colitis patients demonstrate a mixed Th17/Tc17 and Th1/Tc1 mucosal cytokine profile. Mol Immunol 2013, 55:355-364.
48. Fernandez-Banares F., de Sousa M.R., Salas A., et al. Epidemiological risk factors in microscopic colitis: a prospective case-control study. Inflamm Bowel Dis 2013, 19:411-417.
49. Beaugerie L., Pardi D.S. Review article: drug-induced microscopic colitis-proposal for a scoring system and review of the literature. Aliment Pharmacol Ther 2005, 22:277-284.
50. Keszthelyi D., Penders J., Masclee A.A., et al. Is microscopic colitis a drug-induced disease?. JClin Gastroenterol 2012, 46:811-822.
51. Chassany O., Michaux A., Bergmann J.F. Drug-induced diarrhoea. Drug Saf 2000, 22:53-72.
52. Vigren L., Sjoberg K., Benoni C., et al. Is smoking a risk factorforcollagenous colitis?. Scand J Gastroenterol 2011, 46:1334-1339.
53. Yen E.F., Pokhrel B., Du H., et al. Current and past cigarette smoking significantly increase risk for microscopic colitis. Inflamm Bowel Dis 2012, 18:1835-1841.
54. Fernandez-Banares F., de Sousa M.R., Salas A., et al. Impact of current smoking on the clinical course of microscopic colitis. Inflamm Bowel Dis 2013, 19:1470-1476.
55. Miehlke S., Madisch A., Kupcinskas L., et al. Double-blind, double-dummy, randomised, placebo-controlled, multicenter trial of budesonide and mesalazine in collagenous colitis. Gut 2012, 61(Suppl 3):A102.
56. Miehlke S., Madisch A., Bethke B., et al. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2008, 135:1510-1516.
57. Olesen M., Eriksson S., Bohr J., et al. Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut 2004, 53:536-541.
58. Gentile N.M., Abdalla A.A., Khanna S., et al. Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study. Am J Gastroenterol 2013, 108:256-259.
59. Fine K.O.F., Lee E., Lafon G., et al. Randomized, double-blind, placebo-controlled trial of bismuth subsalicylate for microscopic colitis. Gastroenterology 1999, 116:A880.
60. Esteve M., Mahadevan U., Sainz E., et al. Efficacy of anti-TNF therapies in refractory severe microscopic colitis. JCrohns Colitis 2011, 5:612-618.
61. Munch A., Ignatova S., Strom M. Adalimumab in budesonide and methotrexate refractory collagenous colitis. Scand J Gastroenterol 2012, 47:59-63.
62. Pola S., Fahmy M., Evans E., et al. Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis. Am J Gastroenterol 2013, 108:857-858.
63. Pardi D.S., Loftus E.V., Tremaine W.J., et al. Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. Gastroenterology 2001, 120:1483-1484.
64. Munch A., Fernandez-Banares F., Munck L.K. Azathioprine and mercaptopurine in the management of patients with chronic, active microscopic colitis. Aliment Pharmacol Ther 2013, 37:795-798.
65. Riddell J., Hillman L., Chiragakis L., et al. Collagenous colitis: oral low-dose methotrexate for patients with difficult symptoms: long-term outcomes. JGastroenterol Hepatol 2007, 22:1589-1593.
66. Munch A., Bohr J., Vigren L., et al. Lack of effect of methotrexate in budesonide-refractory collagenous colitis. Clin Exp Gastroenterol 2013, 6:149-152.